Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Company Overview

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $2.59 to $3.11
• 50-Day Range: $2.65 to $4.12
• 52-Week Range: $1.61 to $7.42
• Volume: 115,020 shs
• Average Volume: 73,891 shs
• Market Capitalization: $59.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Strong Buy

Aileron Therapeutics Stock Analysis - MarketRank™

Aileron Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 308th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Aileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aileron Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aileron Therapeutics are expected to grow in the coming year, from ($1.41) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aileron Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aileron Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aileron Therapeutics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Aileron Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aileron Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aileron Therapeutics has recently decreased by 8.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aileron Therapeutics does not currently pay a dividend.

Dividend Growth

Aileron Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.19% of the float of Aileron Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aileron Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aileron Therapeutics has recently decreased by 8.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.80

News Sentiment

Aileron Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ALRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Aileron Therapeutics is held by insiders.

Percentage Held by Institutions

90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALRN Stock Analysis - Frequently Asked Questions

How have ALRN shares performed this year?

Aileron Therapeutics' stock was trading at $3.05 at the beginning of 2024. Since then, ALRN stock has decreased by 9.5% and is now trading at $2.76.
View the best growth stocks for 2024 here.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

When did Aileron Therapeutics' stock split?

Aileron Therapeutics's stock reverse split on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Aileron Therapeutics IPO?

Aileron Therapeutics (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' top institutional investors include Geode Capital Management LLC (1.06%), Sigma Planning Corp (0.98%) and KG&L Capital Management LLC (0.06%). Insiders that own company stock include Of Texas/Texas Am I University and James Brian Windsor.
View institutional ownership trends.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALRN
• CUSIP: N/A
• CIK: 1420565
• Web: www.aileronrx.com
• Phone: (617) 995-0900
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.00
• High Stock Price Target: $19.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +588.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,730,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -74.08%
• Return on Assets: -27.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 21,670,000
• Free Float: 20,561,000
• Market Cap: $59.81 million
• Optionable: Not Optionable
• Beta: 2.35